| |  Online-Ressource |
|---|
| Verfasst von: | Stute, Marie [VerfasserIn]  |
|---|
| | Kreysing, Martin [VerfasserIn] |
|---|
| | Zorn, Markus [VerfasserIn] |
|---|
| | Michl, Patrick [VerfasserIn] |
|---|
| | Gauss, Annika [VerfasserIn] |
|---|
| Titel: | Serum amyloid A as a potential biomarker in inflammatory bowel diseases, especially in patients with low C-reactive protein |
|---|
| Verf.angabe: | Marie Stute, Martin Kreysing, Markus Zorn, Patrick Michl, Annika Gauss |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | 18 January 2024 |
|---|
| Umfang: | 14 S. |
|---|
| Fussnoten: | Gesehen am 08.08.2024 |
|---|
| Titel Quelle: | Enthalten in: International journal of molecular sciences |
|---|
| Ort Quelle: | Basel : Molecular Diversity Preservation International, 2000 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 25(2024), 2, Artikel-ID 1177, Seite 1-14 |
|---|
| ISSN Quelle: | 1422-0067 |
|---|
| | 1661-6596 |
|---|
| Abstract: | The acute phase protein Serum Amyloid A (SAA) is synthesised by the liver in response to inflammatory stimuli. Previous studies have revealed that SAA may be a better biomarker of disease activity in inflammatory bowel disease (IBD) compared to C-reactive protein (CRP). This retrospective monocentric study evaluated whether SAA correlates with biomarkers like faecal calprotectin (FC), CRP, the Neutrophil to Lymphocyte ratio (NLR), the platelet count and clinical disease activity of IBD patients. Serum samples from the IBD outpatient clinic of the University Hospital Heidelberg were analysed for SAA concentrations if an FC concentration measurement was available from ±14 days to collection of the serum sample. Three hundred and six serum samples from 265 patients (166 with Crohn’s disease, 91 with ulcerative colitis and 8 with IBD unclassified) met the inclusion criteria. There was a significant positive correlation between SAA and FC, CRP, NLR, platelet count and the Simple Clinical Colitis Activity Index (SCCAI). The cut-off for SAA serum concentration at 4.55 mg/L achieved a sensitivity of 57.5% and a specificity of 69.7% for the detection of active inflammation in IBD. SAA may be used as an additional biomarker in the disease monitoring strategy of IBD patients, especially in patients with low CRP concentrations. |
|---|
| DOI: | doi:10.3390/ijms25021177 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.3390/ijms25021177 |
|---|
| | kostenfrei: Volltext: https://www.mdpi.com/1422-0067/25/2/1177 |
|---|
| | DOI: https://doi.org/10.3390/ijms25021177 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | biomarker |
|---|
| | Crohn’s disease |
|---|
| | inflammatory bowel disease |
|---|
| | SAA |
|---|
| | Serum Amyloid A |
|---|
| | ulcerative colitis |
|---|
| K10plus-PPN: | 1898203415 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Serum amyloid A as a potential biomarker in inflammatory bowel diseases, especially in patients with low C-reactive protein / Stute, Marie [VerfasserIn]; 18 January 2024 (Online-Ressource)
